会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Heterocyclic inhibitors of 5-.alpha.-testosterone reductase
    • 5-α-睾酮还原酶的杂环抑制剂
    • US5302589A
    • 1994-04-12
    • US927091
    • 1992-08-07
    • Stephen V. FryeDavid MiddlemissFrancis G. Fang
    • Stephen V. FryeDavid MiddlemissFrancis G. Fang
    • C07D471/06A61K31/435
    • C07D471/06
    • The present invention relates to certain substituted 17 .beta.-substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 arei) independently hydrogen or lower alkyl and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single or a double bond, orii) taken together are a --CH.sub.2 -- group to form a cyclopropane ring, and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single bond;X is ##STR2## wherein R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are independently hydrogen or lower alkyl,p and q are independently either 0 or 1;R.sup.3 is lower alkyl, lower alkenyl, lower cycloalkyl, lower alkoxy, thiopyridyl, adamantyl, --NR.sup.9 R.sup.10 or --Ar--NR.sup.9 R.sup.10 whereinR.sup.9 and R.sup.10 arei) independently, hydrogen or lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower alkoxy, adamantyl, aryl, benzyl, diphenylmethyl, norbornyl orii) taken together with the linking nitrogen to form a 4 to 8 atom heterocyclic group, ##STR3## wherein; Y represents O, CH.sub.2, --N.dbd., NH or N(lower alkyl) optionally substituted with one or more lower alkyl groups;Ar is an aromatic group of 6 to 12 carbons;R.sup.4 is hydrogen or methyl;Z is --O--, --NH--, --N(lower alkyl), --S--, --SO--, --SO.sub.2, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, CO, CO.sub.2, O.sub.2 C, --N.dbd.N-- --CH.dbd.N-- or --N.dbd.CH--;n and m are independently 0, 1 or 2;and pharmaceutically acceptable salts thereof;their preparation, medical use and pharmaceutical formulations.
    • 本发明涉及式(I)的某些取代的17β-取代的羰基-6-氮杂雄甾-4-烯-3-酮:其中R 1和R 2独立地是氢或低级烷基, 带有R1和R2的碳之间的键是单键或双键,或ii)一起形成-CH 2 - 基以形成环丙烷环,并且具有R 1和R 2的碳之间的键是单键; X为,其中R 5,R 6,R 7和R 8独立地为氢或低级烷基,p和q独立地为0或1; R3为低级烷基,低级烯基,低级环烷基,低级烷氧基,硫代吡啶基,金刚烷基,-NR9R10或-Ar-NR9R10,其中R9和R10为i)独立地为氢或低级烷基,低级烯基,低级炔基,低级环烷基, ,金刚烷基,芳基,苄基,二苯甲基,降冰片基或ii)与连接氮一起形成4至8个原子的杂环基,其中; Y表示任选被一个或多个低级烷基取代的O,CH 2,-N =,NH或N(低级烷基) Ar为6〜12个碳原子的芳香族基团; R4是氢或甲基; Z是-O - , - NH - , - N(低级烷基),-S - , - SO - , - SO 2,-CH 2 CH 2 - , - CH = CH-,CO,CO 2, CH = N-或-N = CH-; n和m独立地为0,1或2; 及其药学上可接受的盐; 其制剂,医疗用途和药物配方。
    • 2. 发明授权
    • 17 .beta.acyl 6 azaandrost-4,6 diazo-4-ene-3-ones
    • 17β酰基6氮杂雄甾-4,6-重氮-4-烯-3-酮
    • US5457098A
    • 1995-10-10
    • US189020
    • 1994-01-28
    • Stephen V. FryeDavid MiddlemissFrancis G. Fang
    • Stephen V. FryeDavid MiddlemissFrancis G. Fang
    • C07D471/06A61K31/435
    • C07D471/06
    • There are disclosed preparation and compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen or lower alkyl or taken together are a --CH.sub.2 -- group to form a cyclopropane ring.X is ##STR2## wherein R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are hydrogen or alkyl,p and q are independently either 0 or 1;R.sup.3 is alkyl, alkenyl, cycloalkyl, alkoxy, thiopyridyl, adamantyl, --NR.sup.9 R.sup.10 or --Ar--NR.sup.9 R.sup.10 whereinR.sup.9 and R.sup.10 are hydrogen or alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, adamantyl, aryl, benzyl, diphenylmethyl, norbornyl, or taken together with the nitrogen to form 4 to 8 atom heterocyclic group, ##STR3## optionally substituted with alkyl groups; Ar is aromaticR.sup.4 is hydrogen or methyl;Z is --O--, --NH--, --N(lower alkyl), --S--, --SO--, --SO.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, CO, CO.sub.2, O.sub.2 C, --N.dbd.N--, --CH.dbd.N--, or --N.dbd.CH--,and n and m are 0, 1 or 2.
    • 公开了式(I)的制备和化合物:其中R 1和R 2是氢或低级烷基或一起是-CH 2 - 基团形成环丙烷环。 X为,其中R 5,R 6,R 7和R 8为氢或烷基,p和q独立地为0或1; R3是烷基,烯基,环烷基,烷氧基,硫代吡啶基,金刚烷基,-NR9R10或-Ar-NR9R10,其中R9和R10是氢或烷基,烯基,炔基,环烷基,烷氧基,金刚烷基,芳基,苄基,二苯基甲基,降冰片基或取代 与氮一起形成4至8个原子的杂环基团,任选被烷基取代; Ar是芳族R 4是氢或甲基; Z是-O - , - NH - , - N(低级烷基),-S - , - SO - , - SO 2 - , - CH 2 CH 2 - , - CH = CH-,CO,CO 2,O 2 C,-N = ,-CH = N-或-N = CH-,n和m为0,1或2。
    • 4. 发明授权
    • Inhibitors of 5-.alpha.-testosterone reductase
    • 5-睾酮还原酶抑制剂
    • US5543406A
    • 1996-08-06
    • US244875
    • 1994-08-15
    • Robert C. AndrewsCynthia M. CribbsStephen V. FryeCurt D. HaffnerPatrick R. Maloney
    • Robert C. AndrewsCynthia M. CribbsStephen V. FryeCurt D. HaffnerPatrick R. Maloney
    • A61K8/63A61K8/00A61K8/49A61K31/565A61Q5/00A61Q19/00C07J73/00A61K31/40A61K31/435A61K31/55
    • C07J73/005
    • The present invention relates to certain substituted 17.beta.-substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), especially those of formula (IG) ##STR1## wherein R.sup.1 and R.sup.2 arei) independently hydrogen or lower alkyl and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single or a double bond, orii) taken together are a --CH.sub.2 -- group to form a cyclopropane ring, and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single bond;R.sup.3c is hydrogen;R.sup.4c is hydrogen, lower alkyl, lower cycloalkyl, lower alkenyl, alkanoyl of 2-6 carbons, --(CH.sub.2).sub.m CO.sub.2 R.sup.16, --(CH.sub.2).sub.m Ar.sup.a, --(CH.sub.2).sub.n 'CONR.sup.17 R.sup.18, --(CH.sub.2).sub.n 'NR.sup.17 R.sup.18 or --(CH.sub.2).sub.n 'OR.sup.16, wherein R.sup.16 is hydrogen, lower alkyl or lower alkenyl; R.sup.17 and R.sup.18 are independently hydrogen, lower alkyl lower cycloalkyl or lower alkenyl; Ar.sup.a is an aromatic group of 6 to 12 carbons; n' is 0 or an integer from 1 to 5; m is an integer from 1 to 5;R.sup.19 and R.sup.20 are independently hydrogen or lower alkyl, or taken together R.sup.19 and R.sup.20 form a carbonyl group (.dbd.O);R.sup.5c is lower alkyl, lower alkenyl, lower cycloalkyl, lower alkoxy, or NR.sup.21 R.sup.22, wherein R.sup.21 and R.sup.22 are independently hydrogen, lower alkyl or lower alkenyl;and pharmaceutically acceptable salts thereof, their preparation, medical use and pharmaceutical formulations.
    • PCT No.PCT / US92 / 11109 Sec。 371日期:1994年8月15日 102(e)日期1994年8月15日PCT提交1992年12月18日PCT公布。 WO / 9313124 PCT公开号 日本公开号为1993年7月8日本发明涉及式(I)的某些取代的17β-取代的羰基-6-氮杂雄甾-4-烯-3-酮,特别是式(I)的那些。 >(IG)其中R1和R2独立地是氢或低级烷基,并且具有R1和R2的碳之间的键是单键或双键,或者ii)一起是-CH 2 - 基团以形成环丙烷环 并且具有R1和R2的碳之间的键是单键; R3c是氢; (CH2)mCO2R16, - (CH2)mAra, - (CH2)n'CONR17R18, - (CH2)n'NR17R18或 - ( CH2)n'OR16,其中R16是氢,低级烷基或低级烯基; R 17和R 18独立地为氢,低级烷基低级环烷基或低级烯基; 阿拉是6至12个碳原子的芳族基团; n'为0或1〜5的整数; m为1〜5的整数; R 19和R 20独立地是氢或低级烷基,或者一起R19和R20形成羰基(= O); R5c是低级烷基,低级烯基,低级环烷基,低级烷氧基或NR21R22,其中R21和R22独立地是氢,低级烷基或低级烯基; 及其药学上可接受的盐,它们的制备,医疗用途和药物制剂。